| A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors (NCT05399654) | Tallac Therapeutics | 2022-06-28 |
| A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001) (NCT05382325) | Merck Sharp & Dohme LLC | 2022-06-16 |
| A Clinical Study to Evaluate the Safety and Tolerability of JS012 in Advanced or Metastatic Solid Tumors (NCT05388279) | Shanghai Junshi Bioscience Co., Ltd. | 2022-04-28 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK114 (NCT05200273) | Akeso | 2022-03-15 |
| A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18) (NCT05017012) | Merck Sharp & Dohme LLC | 2021-09-21 |
| A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors (NCT04875806) | NextCure, Inc. | 2021-06-30 |
| A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors (NCT04866134) | Erasca, Inc. | 2021-05-07 |
| A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors (NCT04670679) | Erasca, Inc. | 2020-12-15 |
| A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid Tumors (NCT04572152) | Akeso | 2020-12-07 |
| A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer (NCT04586270) | Taiho Oncology, Inc. | 2020-10-15 |
| A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors (NCT04381650) | Takeda | 2020-08-17 |
| A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid Tumor (NCT04427774) | Innovent Biologics (Suzhou) Co. Ltd. | 2020-06-29 |
| A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors (NCT04408599) | NextCure, Inc. | 2020-06-10 |
| Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208) (NCT04003623) | Incyte Corporation | 2019-10-31 |
| A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (NCT03849469) | Xencor, Inc. | 2019-05-29 |
| First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors (NCT03616574) | Holy Stone Healthcare Co., Ltd | 2019-04-09 |
| Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors (NCT03684785) | Exicure, Inc. | 2018-12-13 |
| Phase 1 Study of ONO-7475 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors (NCT03730337) | Ono Pharmaceutical Co., Ltd. | 2018-10-17 |
| A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors (NCT03665285) | NextCure, Inc. | 2018-10-01 |
| Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors (NCT03454243) | Hoffmann-La Roche | 2018-02-15 |
| A Study of a New Investigational Medicinal Product to Treat Patients with Advanced or Metastatic Solid Tumors (NCT03316638) | Pierre Fabre Medicament | 2017-11-24 |
| A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors (NCT03248843) | 3D Medicines (Sichuan) Co., Ltd. | 2017-09-15 |
| Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors (NCT03155061) | Ono Pharmaceutical Co., Ltd. | 2017-04-19 |
| A Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours (NCT03082053) | ASLAN Pharmaceuticals | 2017-01-31 |
| A Phase I Study of TAS-102 in Solid Tumors (NCT02261532) | Taiho Pharmaceutical Co., Ltd. | 2014-09-01 |
| A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors (NCT01928394) | Bristol-Myers Squibb | 2013-10-24 |
| Phase I Clinical Study of Metatinib Tromethamine Tablet (NCT02004548) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2013-05-01 |
| E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer (NCT01355302) | Eisai Inc. | 2011-11-01 |
| A Study Evaluating the Bioavailability of Two Formulations of Linifanib and Food Effect on Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors (NCT01506934) | Abbott | 2011-10-01 |
| Dose Escalation of Velcade Daily Dose in Patients With Solid Tumors (NCT02220049) | Gustave Roussy, Cancer Campus, Grand Paris | 2010-12-01 |
| Study of NMS-1286937 in Adult Patients With Advanced/Metastatic Solid Tumors (NCT01014429) | Nerviano Medical Sciences | 2009-11-01 |
| A Phase I/II Clinical Trial of Vidaza With Abraxane in Patients With Advanced/Metastatic Solid Tumors and Breast Cancer (NCT00748553) | University of Utah | 2008-09-01 |
| A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors (NCT00907205) | Semafore Pharmaceuticals | 2007-04-01 |
| A Phase I Study of STA-5312 in Subjects With Advanced or Metastatic Solid Tumors (NCT00276913) | Synta Pharmaceuticals Corp. | 2004-06-01 |